Syrup Glycerol for Raised ICP

What is it?

Mechanism of Action

1. Creates an osmotic gradient between plasma and brain interstitium → draws water out of cerebral tissue into the vascular compartment
2. Reduces brain volume → lowers ICP
3. Osmotic diuresis sustains the hyperosmolar state (serum osmolarity rises to ~355 mOsm/L with repeated dosing)
4. Unlike mannitol and urea, glycerol is metabolized in the liver (enters glycolysis/gluconeogenesis) → less profound systemic dehydration, fewer electrolyte disturbances

"Mannitol, glycerol, and urea are effective in lowering ICP by producing serum hyperosmolarity initially and then causing a diuresis that sustains this state and secondarily causes hypernatremia and hypovolemia." — Adams and Victor's Principles of Neurology, 12th Ed.

Indications

• Cerebral edema (ischemic stroke, meningitis, encephalitis, Reye's syndrome, head injury)
• Raised ICP when IV access is unavailable
• Adjunct to standard ICP management in traumatic intracranial hypertension
• Idiopathic intracranial hypertension (pseudotumor cerebri) — some use

Dose

• Onset: ~30 min (oral)
• Duration: 4–6 hours
• Dilute with equal volume of water or fruit juice to reduce nausea/vomiting

Advantages over Mannitol

Adverse Effects

• Nausea/vomiting (most common with oral use — dilute to reduce)
• Hemolysis (with rapid IV glycerol; not an issue with oral/NG)
• Hyperglycemia (glycerol is metabolized to glucose/pyruvate)
• Electrolyte imbalance — hyponatremia, hypokalemia with prolonged use
• Systemic dehydration (less than mannitol)
• Renal failure — rare, but reported with contaminated IV preparations (ethylene glycol contamination)

Contraindications / Cautions

• Severe hepatic failure (impaired metabolism)
• Uncontrolled diabetes (risk of hyperglycemia)
• Severe dehydration / hypovolemia
• Not recommended for intracerebral hemorrhage — a Cochrane systematic review showed no outcome benefit and possible harm

Practical Notes

• Rebound ICP is less of a concern with glycerol vs. mannitol due to hepatic metabolism
• Monitor serum osmolality (keep <320 mOsm/kg to avoid toxicity), blood glucose, electrolytes, and urine output
• In pediatric practice, it is sometimes preferred over IV mannitol for bacterial meningitis-associated cerebral edema due to ease of administration

Why Vitamin E is Not Indicated for Long-Term Use in Diabetics

The Rationale for Using Vitamin E in Diabetes (Why It Seems Logical)

• Hyperglycemia → advanced glycation end products (AGEs) → free radical generation
• Mitochondrial electron transport chain dysfunction
• NADPH oxidase activation
• Polyol pathway → depletes NADPH (needed to regenerate glutathione)

• Quenches lipid peroxyl radicals in cell membranes and LDL
• Reduces oxidized LDL (a key driver of atherosclerosis)
• Appeared protective in early epidemiological/observational studies

Why Long-Term Use is NOT Indicated — Multiple Mechanisms

1. The Pro-Oxidant Switch (Most Important Biochemical Reason)

"The problem seems to be that vitamin E acts as an antioxidant by forming a stable radical that persists long enough to undergo metabolism to non-radical products. This means that the radical also persists long enough to penetrate deeper into the lipoprotein, causing further radical damage, rather than interacting with a water-soluble antioxidant at the surface." — Harper's Illustrated Biochemistry, 32nd Ed.

• The tocopherol radical (tocopheroxyl radical) formed after quenching a lipid peroxyl radical is relatively stable
• Normally, vitamin C (ascorbate) rapidly regenerates α-tocopherol from this radical
• When vitamin C is insufficient (common in diabetics due to competitive inhibition of glucose on SVCT transporters), the tocopheroxyl radical accumulates and re-enters the lipid phase → initiates further peroxidation
• This is called the "vitamin E-mediated lipid peroxidation" or co-antioxidant depletion effect

2. Quenching of Signaling Radicals

"Nitric oxide and other radicals are important in cell signaling, and especially in signaling for programmed cell death (apoptosis) of cells that have suffered DNA and other damage. It is likely that high concentrations of antioxidants, rather than protecting against tissue damage, may quench the signaling radicals, and so permit the continued survival of damaged cells, increasing the risk of cancer development." — Harper's Illustrated Biochemistry, 32nd Ed.

• Free radicals (ROS, NO) also serve as second messengers for insulin signaling (e.g., H₂O₂ activates PI3K → GLUT4 translocation)
• Chronic high-dose antioxidants may blunt these signaling cascades → worsen insulin resistance
• Also blunts exercise-induced adaptive responses (mitohormesis)

3. Meta-analyses Show Increased Mortality with High-Dose Supplementation

"Meta-analysis of intervention trials with vitamin E shows increased mortality among those taking high-dose supplements." — Harper's Illustrated Biochemistry, 32nd Ed.

• The landmark HOPE trial (NEJM 2000, PMID: 10639540) — 9541 high-risk patients including diabetics — showed no cardiovascular benefit from 400 IU/day vitamin E over 4.5 years
• Miller et al. meta-analysis (2005) showed doses >400 IU/day associated with increased all-cause mortality
• The HOPE-TOO extension found increased risk of heart failure with vitamin E in high-risk patients

4. Haptoglobin Genotype Dependency

• Diabetics with Haptoglobin (Hp) 2-2 genotype may benefit from vitamin E (it improves HDL function and reduces oxidized HDL-lipid peroxides)
• But diabetics with Hp 1-1 or Hp 2-1 genotype derive no benefit and may be harmed
• Since Hp genotype is not routinely tested clinically, blanket supplementation is not justified

5. Interference with Glucose Metabolism

• Vitamin E at pharmacological doses can impair glucose utilization by inhibiting pyruvate dehydrogenase kinase activity in some experimental models
• May also reduce insulin secretion by quenching ROS-dependent signaling in beta cells

Summary Table

Clinical Bottom Line

1. No proven benefit in RCTs (HOPE trial)
2. Potential harm — pro-oxidant effect, increased heart failure, possibly increased mortality at high doses
3. Antioxidant paradox — what helps in vitro or in low-dose dietary form causes harm at supplemental doses
4. Exception: Hp2-2 genotype subgroup may benefit, but this is not yet standard clinical practice

Sources: Harper's Illustrated Biochemistry 32nd Ed; HOPE Trial NEJM 2000 (PMID: 10639540); Zheng et al. J Diabetes Res 2024 (PMID: 39474248)